SCHEMBL2283683

SCHEMBL2283683

Cc1cc(O)c(C(=O)/C=C/c2cccc(OCC#N)c2)c(=O)n1OCC#N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.44
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
APP P05067 1/20 0.40
NR1H4 Q96RI1 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
CYP19A1 P11511 1/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NQO1 P15559 2/20 0.38
CYSLTR2 Q9NS75 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283685 1.00 ABCG2 (0.44) ABCG2ALDH1A1LMNAAPPNR1H4
SCHEMBL2284289 0.89 ABCG2 (0.45) ABCG2ALDH1A1LMNAAPPNR1H4
SCHEMBL2284292 0.89 ABCG2 (0.45) ABCG2ALDH1A1LMNAAPPNR1H4
SCHEMBL2275778 0.85 ABCG2 (0.42) ABCG2ALDH1A1LMNAAPPCYP2C9
SCHEMBL2279872 0.85 ABCG2 (0.42) ABCG2ALDH1A1LMNAAPPNR1H4
SCHEMBL2275776 0.85 ABCG2 (0.42) ABCG2ALDH1A1LMNAAPPCYP2C9
SCHEMBL2277107 0.85 TOP2A (0.47) ABCG2ALDH1A1LMNACYP2C9CYP2C19
SCHEMBL2279866 0.85 ABCG2 (0.42) ABCG2ALDH1A1LMNAAPPNR1H4
SCHEMBL2277109 0.85 TOP2A (0.47) ABCG2ALDH1A1LMNACYP2C9CYP2C19
SCHEMBL2278745 0.84 ABCG2 (0.42) ABCG2ALDH1A1LMNAAPPNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 ABCG2 4878/4885ALDH1A1 576/4885LMNA 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.